What are the challenges in the Emergency & Critical Care Departments?
In both the Emergency Department (ED) and the Critical Care (CC) Department, there are a myriad of challenges – all of which ultimately rest on the ability to rapidly make the right decisions with the help of the right testing. Unfortunately, many healthcare professionals experience slow, complicated to use, incomplete, and unreliable tests to identify pathogens of infectious diseases and accompanying antimicrobial resistance genes. This results in suboptimal patient treatment and management.
In the ED environment, efficient and fast patient triage is key.1 Effective triage algorithms are needed for every, unique case. High-risk patients must be prioritized; safe discharge decisions must be made; overall testing must be reduced for patient comfort and cost containment; and above all, appropriate treatment must be initiated as soon as possible. While speed is of the essence, so is accuracy – because an accurate diagnosis leads to appropriate and timely treatment. Inaccurate or uncertain diagnosis have obvious repercussions on the individual patient, but also affect the whole system, as increased time spent with one patient means other patients are waiting to be seen and treated.
In the critical care environment, an accurate diagnosis is an absolute must in providing the right care, the first time. Timely and precise identification of the medical condition allows physicians to administer the appropriate interventions, medications, and therapies; minimizing potential complications and optimizing patient outcomes. Misdiagnosis or delayed diagnosis can lead to serious consequences, including worsened patient condition, prolonged ICU stays, and even loss of life.
At bioMérieux, we are acutely aware of these challenges and the role that leading-edge diagnostics play in this context. That’s why we look at the whole picture and develop global solutions.
How can bioMérieux Emergency & Critical Care Solutions help?
bioMérieux provides solutions for both emergency and critical care clinicians. In all areas, our solutions offer innovative tests for acute and complex situations that deliver reliable, fast, and actionable results to clinicians. Our tests are easy-to-use and offer confidence in results and workflow efficiency which is crucial in these situations.
Our high-quality immunoassay and syndromic tests and systems ensure reduced patient testing and better-adapted treatment decision for optimal patient care.
Our solutions:
- Limit the number of tests needing to be performed, offering both prevention of delayed patient-care and cost-savings
- Provide better identification of patients with clinically relevant bacterial infections which enables more tailored use of antibiotics 2 and is a key part in fighting antimicrobial resistance, leading to substantial cost savings3
- Enhance the accuracy of diagnosis while reducing direct medical costs by reducing length of stay and number of diagnostic procedures 4,5
We are a partner you can trust because our only motivation is and always has been the same as yours: protecting and improving human health.
Our Emergency & Critical Care Diagnostics Offer
Our global solution of high quality and cost-effective diagnostic tests will help you safely, effectively, and efficiently meet patient needs and contain costs in the Emergency and Critical Care Departments.
Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.
Emergency and Critical Care Solutions for Hospitals/Labs
The easy-to-use VIDAS® Emergency Diagnostics Solution allows you to have all test results in only 20 minutes, with flexibility to work 24/7. VIDAS® Emergency and Critical Care Panel Solutions include markers of cardiac necrosis, heart failure, venous thromboembolism, and severe bacterial infection.
-
VIDAS® D-DIMER EXCLUSION™ II
Safe Exclusion of Venous Thromboembolism
VIDAS® D-Dimer Exclusion™ II is a highly-sensitive automated D-Dimer assay. Used in conjunction with assessment of clinical pretest probability, it allows safe exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE) in both low and intermediate suspected outpatient risk groups in just 20 minutes.
-
VIDAS® B•R•A•H•M•S PCT™
Important Biomarker for Improved Patient Management
Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).
-
VIDAS® High sensitive Troponin I
Optimize the Management of Acute Coronary Syndrome (ACS)
The VIDAS® High sensitive Troponin I assay is intended to be used as an aid in the diagnosis of myocardial infarction delivering actionable results in only 2 hours and for the risk stratification of adult patients with acute coronary syndrome.
-
VIDAS® NT-proBNP2
Exclusion or Confirmation of Acute Heart Failure
VIDAS® NT-proBNP2 is a useful tool for rapid and clinical assessment and diagnosis of patients with symptoms of suspected heart failure.
High sensitivity and specificity allows initiation of timely, appropriate treatment.
Cost-effective tool adapted to emergency situations.
-
VIDAS® NEPHROCHECK®
Reveal Kidney Stress Early. Drive Better Outcomes.
VIDAS® NEPHROCHECK® is an automated test for use on the VIDAS® 3 instrument for the immunoenzymatic quantitative determination of TIMP-2 (Tissue Inhibitor of Metalloproteinase-2) and IGFBP-7 (Insulin-like Growth Factor-Binding Protein 7) proteins in human urine using the ELFA technique (Enzyme Linked Fluorescent Assay).
The VIDAS® NEPHROCHECK® assay is intended to be used in conjunction with clinical evaluation as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) in acutely ill patients.
-
MYACUTECASE™ Mobile App
All the information you need for confident clinical decision- making with the VIDAS® Emergency & Critical Care assays
Designed for healthcare professionals, MYACUTECASE™ is a first-of-its-kind app. Used in conjunction with clinical assessment and other laboratory findings, it provides comprehensive biomarker information and useful tools for:
-
VIDAS® KUBE™
Stackable benchtop automated immunoassay solution
VIDAS® KUBE™ is designed to preserve everything labs appreciate about the VIDAS® Solution combined with advanced technology. VIDAS® KUBE™ is a truly flexible, cost-effective automated immunoassay solution providing fast results in complete confidence.
Emergency Solutions for Hospitals/Labs
bioMérieux also offers the syndromic approach for Emergency Diagnostics solutions. With the BIOFIRE® Solution, clinicians are armed with a valuable tool for helping emergency rooms and other ambulatory settings by enabling a quick diagnosis and timely treatment for a variety of infections: respiratory, gastrointestinal, central nervous system, and joint.
-
BIOFIRE® Respiratory 2.1 and 2.1plus Panels
1 Test. Up to 23 Targets. ~45 Minutes.
The BIOFIRE RP2.1 and RP2.1plus Panels use the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results may enable better-informed diagnosis and treatment of patients.
-
BIOFIRE® FILMARRAY® Gastrointestinal Panel
1 Test. 22 Targets. ~1 Hour.
This alternative method to traditional stool testing is fast, sensitive, and comprehensive with a panel menu that includes bacteria, viruses, and parasites, causing infectious gastroenteritis.
-
BIOFIRE® FILMARRAY® Meningitis/Encephalitis Panel
1 Test. 14 Targets. ~1 Hour.
The BIOFIRE ME Panel provides answers on 14 of the most common bacterial, viral, and yeast pathogens that cause central nervous system infections to help healthcare providers rapidly distinguish between bacterial and viral meningitis and optimize life-saving therapy.
-
BIOFIRE® Joint Infection Panel
1 Test. 39 Targets. ~1 Hour.
Using PCR technology, the BIOFIRE JI Panel is a rapid syndromic test that delivers comprehensive results in one easy-to-read report.
-
BIOFIRE® FILMARRAY® TORCH
Easier testing. Faster results.
Syndromic infectious disease testing with BIOFIRE® FILMARRAY® TORCH is the fastest way to better results.
Emergency Solutions for Point of Care
BIOFIRE® SPOTFIRE® is a multiplex PCR solution for point-of-care testing, offering rapid and actionable results onsite. It provides the ultimate combination of clinical value and operational efficiency in a new simple diagnostic tool for physicians that improves patient care management and support antimicrobial stewardship.
-
BIOFIRE® SPOTFIRE® System
This Changes Everything.
The BIOFIRE® SPOTFIRE® System is the latest advancement in molecular infectious disease diagnostics from bioMérieux for Point-of-Care testing, offering rapid and actionable results onsite.
-
BIOFIRE® SPOTFIRE® Respiratory /Sore Throat Panels
Comprehensive Onsite PCR Results in ~15 Minutes.
The BIOFIRE Respiratory/Sore Throat (R/ST) Panels enable testing for both respiratory or sore throat pathogens on the same panel, providing a flexible respiratory solution to meet the unique needs of point-of-care settings.
Critical Care for Hospitals/Labs
BIOFIRE® syndromic testing solutions provide critical care healthcare professionals with rapid, easy-to-use, and comprehensive PCR tests across a wide range of syndromes that yield accurate and actionable results in ~1 hour.
Fast results make a big difference in critical care, where the right information can lead to improved patient outcomes, optimized patient management, better antimicrobial stewardship, and cumulative cost and time-savings realized throughout the entire patient pathway.
-
BIOFIRE® Blood Culture Identification 2 Panel
1 Test. 43 Targets. ~1 Hour.
The BIOFIRE BCID2 Panel tests for 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeast, and 10 antimicrobial resistance genes – all with one test and with results available in about an hour from positive blood culture.
-
BIOFIRE® FILMARRAY® Meningitis/Encephalitis Panel
1 Test. 14 Targets. ~1 Hour.
The BIOFIRE ME Panel provides answers on 14 of the most common bacterial, viral, and yeast pathogens that cause central nervous system infections to help healthcare providers rapidly distinguish between bacterial and viral meningitis and optimize life-saving therapy.
-
BIOFIRE® FILMARRAY® Pneumonia & Pneumonia plus Panels
1 Test. Up to 34 Targets. ~1 Hour.
Syndromic tests targeting a comprehensive menu of bacteria and viruses that cause pneumonia and other lower respiratory tract infections, as well as 7 genetic markers of antibiotic resistance.
-
BIOFIRE® FILMARRAY® TORCH
Easier testing. Faster results.
Syndromic infectious disease testing with BIOFIRE® FILMARRAY® TORCH is the fastest way to better results.
Useful Resources on Emergency & Critical Care
Contact Us About Emergency & Critical Care Diagnostic Solutions
References
1. Wiler JL, et. al. Optimizing emergency department front-end operations. Ann Emerg Med. 2010;55:142-160.e1
2. Schuetz P, et. al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171:1322-31.
3. Wilke MH, et. al. The use of a standardized PCT-algorithm reduces costs in intensive care in septic patients - a DRG-based simulation model. Eur J Med Res. 2011;16:543-8.
4. Moe GW, et. al. Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115:3103-10.
5. Rutten JH, et. al. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome. Am Heart J. 2008;156:71-7